Navigation Links
The Gift of Hearing Will be Delivered Free to Over 75 Beneficiaries, as Speedway Children's Charities and the Starkey Hearing Foundation Host 'Get in Gear to Help Children Hear'
Date:5/7/2010

sorship, this extraordinary event was made possible.  "It is an honor to be a part of such a spectacular event, one that will change the lives of these children forever, by giving them the gift of hearing," said Saundy Hutto, National Director of New Business Development and Marketing for Speedway Children's Charities. "We are thrilled to team up with the NRA and the Starkey Hearing Foundation to make this event possible. Being able to see the expression on the children's faces when they hear for the first time will be priceless and that is what Speedway Children's Charities is all about."

Through this hearing mission, "Get in Gear to Help Children Hear," the Starkey Hearing foundation will provide hearing devices at no cost. The Starkey Hearing Foundation is a global leader in hearing health care and since 2000 the Foundation has supplied 442,221 hearing aids to people in need throughout 86 countries. Currently the Starkey Hearing Foundation is working toward its goal to deliver one million free hearing aids in this decade. "We live through what we give, and our best work is helping people," said Bill Austin, CEO of the Starkey Hearing Foundation. "We can't do this alone, but together we can say we did something right.

Children will be given the opportunity to hear their first NASCAR race, as each child will receive four tickets to the TECH-NET Auto Service 300, NASCAR Nationwide Series race on May 29, courtesy of Charlotte Motor Speedway.

In addition to the hearing aids and race tickets, each child will also receive a gift bag thanks to donations from AutoTrader.com, PPG Industries, Office Depot Foundation, The Kyle Busch Foundation, Mars Inc. and Otis Spunkmeyer.


'/>"/>
SOURCE Starkey Hearing Foundation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Cochlear Americas Honors Achievements of Cochlear Implant Recipients during Mays Better Hearing & Speech Month
2. FDA Approves First of Its Kind, Fully Implantable (Surgically), Invisible, Prosthetic Hearing Restoration Device
3. FDA Approves First Totally Implanted Hearing System
4. Pew Statement on Congressional Hearing Regarding FDA Drug Safety Reforms
5. Reportlinker Adds U.S. Market for Hearing Aids and Audiology Devices 2010 (Includes Audiologist Survey)
6. Diabetics Twice as Likely to Have Hearing Loss; California HearUSA Centers to Offer Free Hearing Screening and Diabetes Video in March
7. Diabetics Twice as Likely to Have Hearing Loss; New York HearUSA Centers to Offer Free Hearing Screening and Diabetes Video in March
8. Diabetics Twice as Likely to Have Hearing Loss; New Jersey HearUSA Centers to Offer Free Hearing Screening and Diabetes Video in March
9. Diabetics Twice as Likely to Have Hearing Loss; North Carolina HearUSA Centers to Offer Free Hearing Screening and Diabetes Video in March
10. Diabetics Twice as Likely to Have Hearing Loss; Michigan HearUSA Centers to Offer Free Hearing Screening and Diabetes Video in March
11. Diabetics Twice as Likely to Have Hearing Loss; Pennsylvania HearUSA Centers to Offer Free Hearing Screening and Diabetes Video in March
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: AST), ... of regenerative medicine, today announced that the third ... -based Rush University Medical Center in a ... doses of AST-OPC1 (oligodendrocyte progenitor cells) in newly ... spinal cord injury (SCI). This represents the final ...
(Date:8/31/2015)... N.J. and STAMFORD, Conn. ... pharmaceutical subsidiary of Eisai Co., Ltd., and Purdue Pharma ... worldwide collaboration agreement for the development and commercialization of ... orexin receptor antagonist entering Phase III clinical development for ... terms of the agreement, Eisai and Purdue Pharma will ...
(Date:8/31/2015)... , Aug. 31, 2015 Bionomics Limited ... and development of innovative therapeutics for the treatment of ... today announced that its BNC101 IND submission has passed ... Bionomics plans to initiate a Phase 1 clinical trial ... with metastatic pancreatic cancer prior to 31 December 2015. ...
Breaking Medicine Technology:Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 6Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 2Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 3Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 4Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 5Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 2Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 3Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 4
... multiple sclerosis, remained relapse-free after three years of treatment ... active brain lesions - the ... - MS, a devastating disease causing progressive disability, affects 2.5 ... including many young adults - FTY720 regulatory filings planned before ...
... basis of methotrexate,resistance and differences in methotrexate response, ... analysis,of the genetic determinants of resistance to the ... could offer a,pathway to predicting such resistance and ... Children,s Research Hospital study., Besides its use ...
Cached Medicine Technology:FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 2FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 3FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 4FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 5FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 6St. Jude Gene Study Reveals Basis of Anti-Cancer Drug Resistance in Childhood Leukemia 2St. Jude Gene Study Reveals Basis of Anti-Cancer Drug Resistance in Childhood Leukemia 3St. Jude Gene Study Reveals Basis of Anti-Cancer Drug Resistance in Childhood Leukemia 4
(Date:8/31/2015)... West Orange, NJ (PRWEB) , ... September 01, ... ... in the spine to eliminate chronic back pain – once required a long, ... with a shorter hospital stay, less pain, less blood loss and minimal muscle ...
(Date:8/31/2015)... ... 31, 2015 , ... Dental clinicians from Newcastle University, United ... to learn more about its integrated approach to diabetes care. , Philip Preshaw, ... Cellular Medicine at Newcastle University, and Susan Bissett, National Institute for Health Research ...
(Date:8/31/2015)... CA (PRWEB) , ... August 31, 2015 , ... ... center management, recently opened registration for the company’s second Introduction to Hyperbaric Medicine ... held October 15-18, 2015 aboard the Queen Mary Hotel in Long Beach, CA. ...
(Date:8/31/2015)... Ohio (PRWEB) , ... August 31, 2015 , ... ... Michael as Vice President, Marketing and Corporate Communications. In this capacity, Michael will ... , CareSource is an industry leader in consumer-focused programs that have contributed to ...
(Date:8/31/2015)... , ... August 31, 2015 , ... In an ... the Plastic and Reconstructive Surgery Global Open Journal that discusses the future of 3-D ... discussed how, in the future, customized implants, prosthetics, and other 3-D printed tools could ...
Breaking Medicine News(10 mins):Health News:Minimally Invasive Spinal Fusions Squash Back Pain without Arduous Recovery 2Health News:Minimally Invasive Spinal Fusions Squash Back Pain without Arduous Recovery 3Health News:Minimally Invasive Spinal Fusions Squash Back Pain without Arduous Recovery 4Health News:Western Diabetes Institute Collaborates with UK team 2Health News:Western Diabetes Institute Collaborates with UK team 3Health News:Western Diabetes Institute Collaborates with UK team 4Health News:Registration Opens for Wound Care Advantage’s Second UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 2Health News:Registration Opens for Wound Care Advantage’s Second UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 3Health News:Registration Opens for Wound Care Advantage’s Second UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 4Health News:CareSource Names Vice President, Marketing and Corporate Communications 2Health News:Recent Article on 3-D Printing Highlights the Future of Custom Medical Solutions Using the Technology, says Beverly Hills Physicians 2Health News:Recent Article on 3-D Printing Highlights the Future of Custom Medical Solutions Using the Technology, says Beverly Hills Physicians 3
... , ASHEVILLE, N.C. , Jan. ... and smart companies are working hard to adjust their recipes to find ... is one option that is all natural, low in sodium—40% to 70% ... the first and only natural low sodium sea salt. Total sales that ...
... , St. Jude Children,s Research Hospital scientists lead effort ... host of bacterial toxins , MEMPHIS, Tenn. , ... of widely used cholesterol-lowering drugs might help protect individuals from ... pose a deadly threat to those with sickle cell disease. ...
... Acknowledging that the idea of rationing health care, particularly at ... get much rational consideration, a Johns Hopkins emeritus professor of ... an opinion piece featured in this month,s issue of the ... article, John Freeman, M.D., Lederer Professor Emeritus of Pediatric Neurology ...
... from forming, research shows , TUESDAY, Jan. 19 (HealthDay News) ... tobacco known as NNK contributes to the formation of lung ... Taiwan report that NNK contributes to the accumulation of a ... DNMT1 turns off genes that keep tumors from forming. ...
... chromosome lineage reveals farming influence , TUESDAY, Jan. 19 (HealthDay ... farmers who migrated from the Near East 10,000 years ago, ... Y chromosome, which is passed from father to son. , ... by about 110 million men -- it follows a gradient ...
... ... ALS (amyotrophic laterals sclerosis) announced today that it has appointed Gordon S. LaVigne as ... ... ALS Association , the nation’s leader in the fight against the disease ALS ...
Cached Medicine News:Health News:Ocean's Flavor Natural Sea Salt is Helping Companies Reach Low Sodium Goals 2Health News:Ocean's Flavor Natural Sea Salt is Helping Companies Reach Low Sodium Goals 3Health News:Cholesterol-Lowering Drug Shows Promise Against Serious Infections in Sickle Cell Disease 2Health News:Cholesterol-Lowering Drug Shows Promise Against Serious Infections in Sickle Cell Disease 3Health News:Cholesterol-Lowering Drug Shows Promise Against Serious Infections in Sickle Cell Disease 4Health News:Cholesterol-Lowering Drug Shows Promise Against Serious Infections in Sickle Cell Disease 5Health News:Reasoning through the rationing of end-of-life care 2Health News:Gordon S. LaVigne Appointed ALS Association Chief Development and Communications Officer , 2Health News:Gordon S. LaVigne Appointed ALS Association Chief Development and Communications Officer , 3
The Atria 6100 delivers the highest level of clinical performance while incorporating cutting-edge technology to streamline clinic workflow. It offers timely, high-quality, and accurate ECG results c...
The CSV-1000ETDRS10% test face presents the standard ETDRS test at a contrast level of 10%. This test is widely used in clinical studies for the evaluation of refractive surgery and contact lenses....
The CSV-1000SLanC test face provides the same tests as the standard CSV-1000S, except that the acuity test is presented in Landolt C format. , ,This test is very useful when testing patients who cann...
... CSV-1000E contrast sensitivity chart test face is the ... world. This test provides for four (4) rows ... of 8 ft (2.5 meters), these gratings test ... 18 cycles/degree. The CSV-1000E provides a full contrast ...
Medicine Products: